TOBRAMYCIN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H37N5O9
Molecular Weight	467.5145
Optical Activity	UNSPECIFIED
Defined Stereocenters	14 / 14
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TOBRAMYCIN

Structure Search

SMILES

[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O[C@@]2([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O)[C@H]1O)O[C@H](CN)[C@@H](O)C[C@H]3N

InChI

InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N

InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H37N5O9
Molecular Weight	467.5145
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	14 / 14
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:34:08 UTC 2023` Edited by `admin` on `Fri Dec 15 15:34:08 UTC 2023`
Record UNII	VZ8RRZ51VK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOBRAMYCIN

Official Name

English

TOBRAMYCIN [ORANGE BOOK]

Common Name

English

TOBRASONE COMPONENT TOBRAMYCIN

Common Name

English

TOBRAMYCIN [USP MONOGRAPH]

Common Name

English

ZYLET COMPONENT TOBRAMYCIN

Common Name

English

TOBRAMYCIN COMPONENT OF ZYLET

Common Name

English

TOBRAMYCIN [EP MONOGRAPH]

Common Name

English

TOBREX

Brand Name

English

TOBRAMYCIN [JAN]

Common Name

English

TOBRAMYCIN [HSDB]

Common Name

English

tobramycin [INN]

Common Name

English

NEBRAMYCIN VI

Common Name

English

TOBRAMYCIN [MI]

Common Name

English

TOBRADEX ST COMPONENT TOBRAMYCIN

Common Name

English

AKTOB

Brand Name

English

NEBRAMYCIN FACTOR 6

Common Name

English

TOBRAMYCIN [VANDF]

Common Name

English

47663

Code

English

TOBRAMYCIN COMPONENT OF TOBRADEX

Common Name

English

KITABIS PAK

Brand Name

English

TOBRAMYCIN COMPONENT OF TOBRADEX ST

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4))-2-DEOXY-

Common Name

English

VANTOBRA

Brand Name

English

O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1.ALPHA.6))-2-DEOXY-L-STREPTAMINE

Common Name

English

TOBRAMYCIN COMPONENT OF TOBRASONE

Common Name

English

TOBI PODHALER

Brand Name

English

NSC-180514

Code

English

TOBRAMYCIN [USAN]

Common Name

English

TOBRAMYCIN [MART.]

Common Name

English

TOBRAMYCIN [USP-RS]

Common Name

English

Tobramycin [WHO-DD]

Common Name

English

TOBI

Brand Name

English

TOBRADEX COMPONENT TOBRAMYCIN

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000007853

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

NCI_THESAURUS

C2363

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

WHO-ATC

S01AA12

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

WHO-VATC

QJ01GB01

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

EU-Orphan Drug

EU/3/06/366

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

FDA ORPHAN DRUG

84494

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

LIVERTOX

NBK548505

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

WHO-VATC

QS01AA12

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

FDA ORPHAN DRUG

271908

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

FDA ORPHAN DRUG

278009

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

CFR

21 CFR 862.3900

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

WHO-ATC

J01GB01

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

NDF-RT

N0000175477

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

FDA ORPHAN DRUG

281709

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

EMA ASSESSMENT REPORTS

VANTOBRA (AUTHORIZED: CYSTIC FIBROSIS)

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

EMA ASSESSMENT REPORTS

TOBI PODHALER (AUTHORIZED: CYSTIC FIBROSIS)

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

FDA ORPHAN DRUG

121098

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

Code System Code Type Description

NSC

180514

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

CAS

32986-56-4

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

EPA CompTox

DTXSID8023680

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

LACTMED

Tobramycin

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

NCI_THESAURUS

C62082

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

RS_ITEM_NUM

1667508

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

INN

2990

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

CHEBI

73678

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

PUBCHEM

36294

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

FDA UNII

VZ8RRZ51VK

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

EVMPD

SUB11134MIG

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

MESH

D014031

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

DAILYMED

VZ8RRZ51VK

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

ECHA (EC/EINECS)

251-322-5

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

ChEMBL

CHEMBL1747

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

CHEBI

28864

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

DRUG CENTRAL

2684

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

RXCUI

10627

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

RxNorm

WIKIPEDIA

TOBRAMYCIN

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

MERCK INDEX

m10917

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

Merck Index

HSDB

3259

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

SMS_ID

100000091065

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

DRUG BANK

DB00684

Created by admin on Fri Dec 15 15:34:08 UTC 2023 , Edited by admin on Fri Dec 15 15:34:08 UTC 2023

PRIMARY

Related Record Type Details


					HJT0RXD7JK

TOBRAMYCIN SULFATE

SALT/SOLVATE -> PARENT

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

ROUTE OF ADMINISTRATION: INJECTION

Interaction Type:

BINDING

Amount:

Related Record Type Details


					5981U00LY0

NEAMINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					15JT14C3GI

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					NT4ZW65UWG

NEBRAMINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					VZ8RRZ51VK

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MIC	BIOLOGICAL				ROUTE OF ADMINISTRATION: INJECTION SUSCEPTIBILITY: RESISTANT

Biological Half-life	PHARMACOKINETIC				POPULATION: NEONATES ≥ 1200 GRAMS

Tmax	PHARMACOKINETIC				DOSAGE FORM: POWDER ROUTE OF ADMINISTRATION: ORAL INHALATION

Volume of Distribution	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: INJECTION POPULATION: CHILDREN

Biological Half-life	PHARMACOKINETIC				POPULATION: INFANTS

Biological Half-life	PHARMACOKINETIC				POPULATION: CHILDREN

Volume of Distribution	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: INJECTION POPULATION: NEONATES

Volume of Distribution	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: INJECTION POPULATION: ADULTS

Biological Half-life	PHARMACOKINETIC				DOSAGE FORM: POWDER ROUTE OF ADMINISTRATION: ORAL INHALATION

Biological Half-life	PHARMACOKINETIC				POPULATION: NEONATES ≤ 1200 GRAMS

MIC	BIOLOGICAL				PATHOGEN: LOW ORDER OF ACTIVITY AGAINST MOST GRAM-POSITIVE ORGANISMS INCLUDING S. PNEUMONIAE, S. PYOGENES, AND ENTEROCOCCI SUSCEPTIBILITY: SUSCEPTIBLE PATHOGEN: S. AUREUS, CITROBACTER spp., ENTEROBACTER spp., E. COLI, KLEBSIELLA spp., MORGANELLA MORGANII, P. AEURUGINOSA, P. MIRABILIS, PROTEUS VULGARIS, PROVIDENCIA spp., SERRATIA spp. ROUTE OF ADMINISTRATION: INJECTION

Tmax	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: IM

Volume of Distribution	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: INJECTION POPULATION: INFANTS

Volume of Distribution	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: ORAL INHALATION DOSAGE FORM: POWDER POPULATION: TYPICAL CYSTIC FIBROSIS PATIENTS

Biological Half-life	PHARMACOKINETIC				POPULATION: ADULTS WITH IMPAIRED RENAL FUNCTION

Tmax	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: IIV

Biological Half-life	PHARMACOKINETIC				DOSAGE FORM: SOLUTION ROUTE OF ADMINISTRATION: ORAL INHALATION

Biological Half-life	PHARMACOKINETIC				POPULATION: ADOLESCENTS

MIC	BIOLOGICAL				SUSCEPTIBILITY: INTERMEDIATE ROUTE OF ADMINISTRATION: INJECTION

Biological Half-life	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: IV POPULATION: ADULTS

Volume of Distribution	PHARMACOKINETIC				ROUTE OF ADMINISTRATION: INJECTION POPULATION: ADOLESCENTS